Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study. [electronic resource]
Producer: 20190409Description: 649-659 p. digitalISSN:- 1474-5488
- Aged
- Antineoplastic Agents -- administration & dosage
- Benzamides -- administration & dosage
- Biphenyl Compounds
- Dose-Response Relationship, Drug
- Enhancer of Zeste Homolog 2 Protein -- antagonists & inhibitors
- Enzyme Inhibitors -- administration & dosage
- Female
- France
- Humans
- Lymphoma, B-Cell -- drug therapy
- Male
- Maximum Tolerated Dose
- Middle Aged
- Morpholines
- Pyridones -- administration & dosage
- Time Factors
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.